Upgrade to SI Premium - Free Trial

Pfizer (PFE) Says New Sub-group Analyses from Tafamidis Phase 3 ATTR-ACT Study Presented at HFSA

September 18, 2018 9:04 AM
Pfizer Inc. (NYSE: PFE) announced today that additional sensitivity and post-hoc analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles